NASDAQ •
Healthcare •
Biotechnology •
Quote as of 08/28/2026
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization93.51 mln
Float48.95 mln
Earnings Date11/04/2026
Piotroski F-Score
3
/ 9
Below average
1-Year Forecast
6.60
Transformational upside
Relative Strength
24
/ 100
Significantly lagging
Debt / Equity
0.37
Low leverage
ROE
-53.76
Deeply negative
Dividend Yield
0.00%
No dividend
Business Description
Aldeyra Therapeutics is a Massachusetts-based biotechnology company focused on developing treatments for immune-related conditions. Its most advanced drug candidates include reproxalap, currently in late-stage trials for dry eye disease and eye allergies, and ADX-2191, which targets rare eye cancers and retinal disorders. The company is also testing an oral medication called ADX-629 for conditions ranging from asthma and psoriasis to COVID-19. Founded in 2004, Aldeyra continues to build a broader pipeline of experimental therapies aimed at addressing a wide range of inflammatory diseases.
